Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Percutaneous coronary angioplasty

Percutaneous coronary intervention (PCI) is one of a host of techniques performed by using a catheter inserted via a major limb artery that aims to relieve nanowing of coronary arteries. For example, percutaneous transluminal coronary angioplasty (PTCA) is the classic PCI that uses a catheter-directed balloon to dilate a stenotic coronary artery, and more recent PCIs include stent implantation, rotational atherectomy, and laser angioplasty. [Pg.938]

PT Pertussis toxin PTCA Percutaneous transluminal coronary angioplasty PTCR Percutaneous transluminal coronary recanalization Pte-H Tetrahydropteridine PUFA Polyunsaturated fatty acid PUMP-1 Punctuated metalloproteinase also known as matrilysin... [Pg.285]

Coronary interventions (coronary bypass, percutaneous transluminal coronary angioplasty, or stents)... [Pg.181]

PTCA Percutaneous transluminal coronary angioplasty Sao2 Arterial oxygen percent saturation... [Pg.1557]

Cardiac catheterization and coronary angiography are used in patients with suspected CAD to document the presence and severity of disease as well as for prognostic purposes. Interventional catheterization is used for thrombolytic therapy in patients with acute MI and for managing patients with significant CAD to relieve obstruction through percutaneous transluminal coronary angioplasty, atherectomy, laser treatment, or stent placement. [Pg.146]

Perchlorotoluene, 6 327 Perchlorylation, 12 183 Perchloryl fluoride, 18 279 Percolation leaching, 16 153 Percolation processes of filled polymers, 11 303 for wood, 26 358-359 Percolation theory, 20 345 23 63 Percolation transition, 10 16 Percutaneous transluminal coronary angioplasty (PTCA), 3 712 -per- designation, 7 609t PE resins, applications of, 20 206t. See also Polyethylene (PE)... [Pg.681]

Inoue T, Sakai Y, Morooka S, Hayashi T, Takayanagi K, Takabatake Y. Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1996 28 1127-1133. [Pg.202]

The safety and efficacy of bivalirudin have not been established in patients with acute coronary syndromes who are not undergoing percutaneous transluminal coronary angioplasty (PTCA) or percutaneous coronary intervention (PCI). [Pg.157]

PTCA percutaneous transluminal coronary angioplasty PTH parathyroid hormone PTT partial thromboplastin time PUD peptic ulcer disease pulm pulmonary PVC premature ventricular contraction... [Pg.449]

Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris outcomes for patients with double-vessel versus single—vessel coronary artery disease in a Vererans Affairs cooperative randomized trial. J Am Coll Cardiol 1997 29 1505. [Pg.81]

Rodriguez A, Boullon F, Perez-Balino N, et al. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease in-hospital results and 1 year follow-up. J Am Coll Cardiol 1993 22 1060. [Pg.82]

Rothbaum DA, Linnemeier TJ, Landin RJ, et al. Emergency percutaneous transluminal coronary angioplasty in acute myocardial infarction a 3 year experience. J Am Coll Cardiol 1987 10 264-272. [Pg.82]

Maillard L, Hamon M, Khalife K, et al. A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2000 35 1729-1736. [Pg.83]

Lefkovits J, Ivanhoe RJ, Califf RM, et al. Effects of platelet glycoprotein llb/llla receptor blockade by a chimeric monoclonal antibody on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction (EPIC). Am J Cardiol 1996 77 1045-1051. [Pg.83]

Stevens T, Kahn JK, McCallister BD, et al. Safety and efficacy of percutaneous transluminal coronary angioplasty in patients with left ventricular dysfunction. Am J Cardiol 1991 68 313-319. [Pg.84]

Contraindications Active internal bleeding, arteriovenous malformation or aneurysm, cerebrovascular accident (CVA) with residual neurologic defect, history of CVA (within the past 2 yr) or oral anticoagulant use within the past 7 days unless PT is less than 1.2 X control, history of vasculitis, hypersensitivity to murine proteins, intracranial neoplasm, prior IV dextran use before or during percutaneous transluminal coronary angioplasty (PTCA), recent surgery or trauma (within the past 6 wk), recent (within the past 6 wk or less) GI or GU bleeding, thrombocytopenia (less than 100,000 cells/pl), and severe uncontrolled hypertension... [Pg.2]

Anticoagulant in patients with unstable angina who are undergoing percutaneous transluminal coronary angioplasty (PTCA) in conjunction with aspirin IV 0 75 mg/kg as IV bolus followed by IV infusion at rate of 1.75 mg/kg/hr for duration of procedure. After initial 4-hr infusion is completed, may give additional IV infusion at rate of 0.2 mg/ kg/hr for 20 hr or less, if necessary. [Pg.148]

It is indicated for platelet aggregation inhibition as adjunct to percutaneous transluminal coronary angioplasty or atherectomy (PTCA). [Pg.246]

Recommended dosage and monitoring requirements The recommended dosage of ReoPro is an intravenous bolus of 0.25mg/kg administered 10 to 60 minutes before the start of percutaneous transluminal coronary angioplasty (PTCA), followed by a continuous infusion of 0.125 pg/kg per... [Pg.308]

Use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PCTA) intended for use with asprin... [Pg.479]

The drug has a short half-life with clearance that is 20% renal and the remainder metabolic. Bivalirudin also inhibits platelet activation and has been FDA-approved for use in percutaneous coronary angioplasty. [Pg.761]

In 814 patients randomly allocated to fish oils for 18 weeks for the reduction of re-stenosis after percutaneous transluminal coronary angioplasty, gastrointestinal adverse effects, most commonly bloating and burping, were reported in 37% of patients taking fish oils, versus 31% of those taking placebo (13). [Pg.542]

Cairns JA, Gill J, Morton B, Roberts R, Gent M, Hirsh J, Holder D, Finnie K, Marquis JF, Naqvi S, Cohen E. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study. Circulation 1996 94(7) 1553-60. [Pg.543]

PAD=peripheral arterial disease PTA=percutaneous transluminal angioplastry PTCA=DA= directional atherectomy PTCA=percutaneous transluminal coronary angioplasty. [Pg.450]

Vascular stenting has become a common procedure during percutaneous transluminal angioplasty (PTA) and percutaneous transluminal coronary angioplasty (PTCA) procedures because it has been found to reduce restenosis (Narins et al., 1998). In both the STRESS (Stent Restenosis Study) and BENESTENT... [Pg.451]

See other pages where Percutaneous coronary angioplasty is mentioned: [Pg.180]    [Pg.255]    [Pg.186]    [Pg.73]    [Pg.82]    [Pg.149]    [Pg.153]    [Pg.184]    [Pg.46]    [Pg.71]    [Pg.133]    [Pg.262]    [Pg.537]    [Pg.116]    [Pg.243]    [Pg.7]    [Pg.412]   


SEARCH



Angioplasty

Coronary angioplasty

Percutaneous

Percutaneous angioplasty

© 2024 chempedia.info